NASDAQ:IPHA Innate Pharma Q4 2025 Earnings Report $1.78 +0.02 (+1.14%) Closing price 07/24/2026 03:59 PM EasternExtended Trading$1.78 +0.00 (+0.28%) As of 07/24/2026 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Innate Pharma EPS ResultsActual EPS-$0.18Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AInnate Pharma Revenue ResultsActual Revenue$2.41 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AInnate Pharma Announcement DetailsQuarterQ4 2025Date2/14/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsInnate Pharma's Q2 2026 earnings is estimated for Thursday, September 17, 2026, based on past reporting schedules, with a conference call scheduled at 9:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile Innate Pharma Earnings HeadlinesOncolytics Biotech (NASDAQ:ONCY) versus Innate Pharma (NASDAQ:IPHA) Critical ContrastJuly 24 at 2:14 AM | americanbankingnews.comInnate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology ConferenceJuly 23 at 1:00 AM | businesswire.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.July 25 at 1:00 AM | InvestorPlace (Ad)Innate Pharma Corporate Event Calendar | NASDAQ:IPHAJuly 5, 2026 | benzinga.comInnate Pharma to participate in the Jefferies Global Healthcare ConferenceMay 19, 2026 | businesswire.comInnate Pharma S.A. (NASDAQ:IPHA) Q1 2026 Earnings Call TranscriptMay 14, 2026 | insidermonkey.comSee More Innate Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Innate Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Innate Pharma and other key companies, straight to your email. Email Address About Innate PharmaInnate Pharma (NASDAQ:IPHA) SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments. The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca. In addition to monalizumab, Innate Pharma’s pipeline includes multiple early- to late-stage candidates such as IPH5201 (anti-TIM-4) and IPH6101 (anti-IL-1RAP), which aim to broaden therapeutic options across solid tumors and hematological malignancies. These assets reflect Innate Pharma’s commitment to advancing precision immunotherapies through strategic partnerships and rigorous clinical development. Since its inception, Innate Pharma has established a global footprint, conducting multi-center clinical trials across Europe and North America. The company’s research facilities in Marseille support a multidisciplinary team of scientists, clinicians and regulatory experts focused on biomarker-driven approaches. Through collaborations with major pharmaceutical companies, Innate Pharma leverages complementary expertise to accelerate the translation of its discovery efforts into the clinic. Led by a management team with deep experience in biotechnology product development, Innate Pharma maintains a strategic focus on unlocking the potential of innate immunity for cancer treatment. The company’s operations benefit from a robust intellectual property portfolio and a track record of forging alliances that enhance its capacity to deliver innovative oncology solutions to patients worldwide.View Innate Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/20- 07/24Telecom Earnings Reveal a Sector That Finally Looks HealthierAMD and Cerbras Create A New Blueprint For HardwareIntel Earnings Reveal Whether the Chip Selloff Created a BuyDefense Earnings Show Readiness Now and Modernization AheadFreeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good EnoughTesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Upcoming Earnings Baker Hughes (7/26/2026)Nucor (7/27/2026)Cadence Design Systems (7/27/2026)Coca Cola Femsa (7/27/2026)Welltower (7/27/2026)Astrazeneca (7/27/2026)PACCAR (7/28/2026)Ford Motor (7/28/2026)Boeing (7/28/2026)Ecolab (7/28/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
